Brain-derived neurotrophic factor is elevated in the blood serum of Crohn's disease patients, but is not influenced by anti-TNF-α treatment-A pilot study.
Adult
Affect
/ drug effects
Brain-Derived Neurotrophic Factor
/ blood
Crohn Disease
/ blood
Depression
/ drug therapy
Female
Humans
Male
Middle Aged
Pain
/ drug therapy
Pain Measurement
Pilot Projects
Prospective Studies
Psychiatric Status Rating Scales
Sleep
/ drug effects
Sleep Initiation and Maintenance Disorders
/ etiology
Treatment Outcome
Tumor Necrosis Factor Inhibitors
/ therapeutic use
BDNF
Crohn's disease
anti-TNF-α
pain
sleep
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
14
07
2020
received:
30
03
2020
accepted:
01
08
2020
pubmed:
2
9
2020
medline:
11
1
2022
entrez:
2
9
2020
Statut:
ppublish
Résumé
Brain-derived neurotrophic factor (BDNF) is associated with depression, pain, or sleep disorders, factors that are thought to be involved in the pathogenesis and clinical course of Crohn's disease (CD). Therefore, the study aimed at assessing the BDNF serum level in patients with CD and evaluates the effect of anti-TNF-α therapy on the BDNF level and its impact on sleep, mood, and pain parameters. Fifty-eight CD patients and 26 healthy controls (HC) were included in the study. The severity of insomnia symptoms was assessed by the Athens Insomnia Scale (AIS). Subjective pain intensity was estimated by the Visual Analogue Scale (VAS) and Laitinen Pain Scale. Mood level was measured using the Beck Depression Inventory (BDI). Seventeen patients were treated with anti-TNF-α therapy for 14 weeks and were re-examined after treatment. CD patients had a higher serum BDNF level than HC (P = .010). No correlation between clinical severity and BDNF was found. There were positive correlations between the BDNF level and the results of AIS (r = 0.253, P = .020), the severity of pain measured using the VAS (r = 0.251, P = .021) and the Laitinen Pain Scale (r = 0.218, P = .047), but not BDI. No differences were observed in the BDNF level before and after 14 weeks of anti-TNF-α therapy. Increased BDNF level in CD patients suggests that it may be involved in the pathogenesis and clinical course of the disease. Further research into BDNF might contribute to a better understanding of the effects of sleep and pain on the course of CD.
Sections du résumé
BACKGROUND
Brain-derived neurotrophic factor (BDNF) is associated with depression, pain, or sleep disorders, factors that are thought to be involved in the pathogenesis and clinical course of Crohn's disease (CD). Therefore, the study aimed at assessing the BDNF serum level in patients with CD and evaluates the effect of anti-TNF-α therapy on the BDNF level and its impact on sleep, mood, and pain parameters.
METHODS
Fifty-eight CD patients and 26 healthy controls (HC) were included in the study. The severity of insomnia symptoms was assessed by the Athens Insomnia Scale (AIS). Subjective pain intensity was estimated by the Visual Analogue Scale (VAS) and Laitinen Pain Scale. Mood level was measured using the Beck Depression Inventory (BDI). Seventeen patients were treated with anti-TNF-α therapy for 14 weeks and were re-examined after treatment.
KEY RESULTS
CD patients had a higher serum BDNF level than HC (P = .010). No correlation between clinical severity and BDNF was found. There were positive correlations between the BDNF level and the results of AIS (r = 0.253, P = .020), the severity of pain measured using the VAS (r = 0.251, P = .021) and the Laitinen Pain Scale (r = 0.218, P = .047), but not BDI. No differences were observed in the BDNF level before and after 14 weeks of anti-TNF-α therapy.
CONCLUSIONS AND INFERENCES
Increased BDNF level in CD patients suggests that it may be involved in the pathogenesis and clinical course of the disease. Further research into BDNF might contribute to a better understanding of the effects of sleep and pain on the course of CD.
Substances chimiques
Brain-Derived Neurotrophic Factor
0
Tumor Necrosis Factor Inhibitors
0
BDNF protein, human
7171WSG8A2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13978Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Lommatzsch M, Braun A, Mannsfeldt A, et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia: implications for paracrine and target-derived neurotrophic functions. Am J Pathol. 1999;155(4):1183-1193.
Al-Qudah M, Alfagih M, Al-Shboul O, Saadeh R, Al-Dwari A. Effect of cytokine treatment on the expression and secretion of brain derived neurotrophic factor in the smooth muscle of the rat colon. Bimed Rep. 2020;13(1):55-60.
Serra MP, Poddighe L, Boi M, et al. Effect of acute stress on the expression of BDNF, trkB, and PSA-NCAM in the hippocampus of the roman rats: a genetic model of vulnerability/resistance to stress-induced depression. Int J Mol Sci. 2018;19(12):3745.
Kurina LM, Goldacre MJ, Yeates D, Gill LE. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health. 2001;55(10):716-720.
Byrne G, Rosenfeld G, Leung Y, et al. Prevalence of anxiety and depression in patients with inflammatory bowel disease. Can J Gastroenterol Hepatol. 2017;2017:1-6.
Merighi A, Salio C, Ghirri A, et al. BDNF as a pain modulator. Prog Neurogibol. 2008;85(3):297-317.
Yu YB, Zuo XL, Zhao QJ, et al. Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut. 2012;61(5):685-694.
Monteiro BC, Monteiro S, Candida M, et al. Relationship between brain-derived neurotrofic factor (Bdnf) and sleep on depression: a critical review. Clin Pract Epidemiol Ment Heal. 2017;13(1):213-219.
Giese M, Unternährer E, Hüttig H, et al. BDNF: an indicator of insomnia. Mol Psychiatry. 2014;19(2):151-152.
Deuschle M, Schredl M, Wisch C, et al. Serum brain-derived neurotrophic factor (BDNF) in sleep-disordered patients: relation to sleep stage N3 and rapid eye movement (REM) sleep across diagnostic entities. J Sleep Res. 2018;27(1):73-77.
Jang S-W, Liu X, Pradoldej S, et al. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci. 2010;107(8):3876-3881.
Hon CY, Nicol AM. Examining the association between insomnia and bowel disorders in Canada: is there a trend? UBC Med J. 2010;2(1):11-15.
Ananthakrishnan AN, Long MD, Martin CF, Sandler RS, Kappelman MD. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol. 2013;11(8):965-971.
Sonnenberg A. Occupational distribution of inflammatory bowel disease among German employees. Gut. 1990;31(9):1037-1040.
Sofia MA, Lipowska AM, Zmeter N, Perez E, Kavitt R, Rubin DT. Poor sleep quality in Crohn's disease is associated with disease activity and risk for hospitalization or surgery. Inflamm Bowel Dis. 2020;26(8):1251-1259.
Gingold-Belfer R, Peled N, Levy S, et al. Impaired sleep quality in Crohn's disease depends on disease activity. Dig Dis Sci. 2014;59(1):146-151.
Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci. 2014;8:430.
Bałkowiec-Iskra E, Vermehren-Schmaedick A, Balkowiec A. Tumor necrosis factor-α increases brain-derived neurotrophic factor expression in trigeminal ganglion neurons in an activity-dependent manner. Neuroscience. 2011;180:322-333.
Sochal M, Krzywdzinska M, Gabryelska A, Talar-Wojnarowska R, Malecka-Panas E. Efficiency and safety of one-year anti-TNF-α treatment in Crohn's disease: a Polish single-centre experience. Prz Gastroenterol. 2020;15(2):156-160.
Sochal M, Krzywdzińska M, Gabryelska A, et al. A simple index to predict the efficiency of adalimumab treatment in Crohn's disease with a limited duration of therapy. Pol Arch Intern Med. 2020. https://doi.org/10.20452/pamw.15507 [Epub ahead of print].
Forsgren S, Grimsholm O, Dalén T, Rantapää-Dahlqvist S. Measurements in the blood of BDNF for RA patients and in response to anti-TNF treatment help us to clarify the magnitude of centrally related pain and to explain the relief of this pain upon treatment. Int J Inflam. 2011;2011:1-7.
Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet (London, England). 1980;315(8167):514.
Fornal-Pawłowska M, Wołyńczyk-Gmaj D, Szelenberger W. Validation of the Polish version of the Athens Insomnia Scale. Psychiatr Pol. 2011;45(2):211-221.
Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48(6):555-560.
Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969;62(10):989-993.
Laitinen J. Acupuncture and transcutaneous electric stimulation in the treatment of chronic sacrolumbalgia and ischialgia. Am J Chin Med. 1976;4(2):169-175.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-571.
Zheng Q, Xu MJ, Cheng J, Chen JM, Zheng L, Li ZG. Serum levels of brain-derived neurotrophic factor are associated with depressive symptoms in patients with systemic lupus erythematosus. Psychoneuroendocrinology. 2017;78:246-252.
Steinkamp M, Schulte N, Spaniol U, et al. Brain derived neurotrophic factor inhibits apoptosis in enteric glia during gut inflammation. Med Sci Monit. 2012;18(4):BR117-22.
Liang J, Deng G, Huang H. The activation of BDNF reduced inflammation in a spinal cord injury model by TrkB/p38 MAPK signaling. Exp Ther Med. 2019;17:1688-1696.
Obata K, Noguchi K. BDNF in sensory neurons and chronic pain. Neurosci Res. 2006;55(1):1-10.
Al-Qudah M, Shammala DA, Al-Dwairi A, Al-Shboul O, Mustafa AG. Dextran sodium sulphate (DSS)-induced colitis alters the expression of neurotrophins in smooth muscle cells of rat colon. Physiol Res. 2017;66(6):1009-1020.
Fujiwara T, Kono S, Katakura K, et al. Evaluation of brain activity using near-infrared spectroscopy in inflammatory bowel disease patients. Sci Rep. 2018;8(1):402.
Grimsholm O, Rantapää-Dahlqvist S, Dalén T, Forsgren S. BDNF in RA: downregulated in plasma following anti-TNF treatment but no correlation with inflammatory parameters. Clin Rheumatol. 2008;27(10):1289-1297.
Sikandar S, Minett MS, Millet Q, et al. Brain-derived neurotrophic factor derived from sensory neurons plays a critical role in chronic pain. Brain. 2018;141(4):1028-1039.
Yajima Y, Narita M, Narita M, Matsumoto N, Suzuki T. Involvement of a spinal brain-derived neurotrophic factor/full-length TrkB pathway in the development of nerve injury-induced thermal hyperalgesia in mice. Brain Res. 2002;958(2):338-346.
Xue J, Li H, Xu Z, et al. Paradoxical sleep deprivation aggravates and prolongs incision-induced pain hypersensitivity via BDNF signaling-mediated descending facilitation in rats. Neurochem Res. 2018;43(12):2353-2361.
He HY, Tian JL, Deng YQ, et al. Association of brain-derived neurotrophic factor levels and depressive symptoms in young adults with acne vulgaris. BMC Psychiatry. 2019;19(1):193.
Sjahrir M, Roesyanto-Mahadi ID, Effendy E. Correlation between serum brain-derived neurotrophic factor level and depression severity in psoriasis vulgaris patients. Open Access Maced J Med Sci. 2019;7(4):583-586.
Panek M, Jonakowski M, Zioło J, et al. Identification of relationships between interleukin 15 mRNA and brain-derived neurotrophic factor II mRNA levels with formal components of temperament in asthmatic patients. Mol Neurobiol. 2017;54(3):1733-1744.